Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ovid Therapeutics Inc. (OVID)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.7400-0.0100 (-0.57%)
At close: 04:00PM EDT
1.6800 -0.06 (-3.45%)
After hours: 07:57PM EDT
Advertisement
Sign in to post a message.
  • M
    Mark
    Does anyone know why the sharp dropoff - is it just following the market down or are there any specific issues?
  • N
    NSX
    I used to held shares during Takada… but oh man, is depressing!
    Bearish
  • R
    Rohn
    What about the patent for Alzheimer's OVID recently received.
    I can't find more info about it.
    Neutral
  • J
    Jason
    I understand some will be selling right now at the moment to take profits, no problem, been here since $2 range and i'll go to the end of the tunnel till they have something to sell ! Angelman is 1/2 done with phase 3 & Fragile X is done with phase 2. This company did not have a single revenue so far, by the time they'll have something to sell, our shares will soar in value ! Then i'll sell and buy myself a bottle of Champagne ! Value investor here !
    Bullish
  • K
    Kash
    Shares of Ovid Therapeutics Inc (NASDAQ:OVID) have been assigned an average recommendation of "Buy" from the eleven analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell re
    Shares of Ovid Therapeutics Inc (NASDAQ:OVID) have been assigned an average recommendation of "Buy" from the eleven analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell re
    www.marketbeat.com
    Bullish
  • S
    Sajid
    Ovid Therapeutics has a consensus target price of $22.67, indicating a potential upside of 317.43%.
    Bullish
  • O
    Olz
    What’s everyone’s hold/exit strategy? I’ve been in here for over a year because I think this company has great potential, still can’t believe they failed OV101.
  • D
    Drew
    Should be great price action accumulating prior 05/07/2019
    Phase 3 trial planned for 2H 2019. Phase 2 data to be presented at AAN May 7, 2019.
  • l
    lor
    Waiting patiently for the data results of the phase 2, but it’s pretty obvious the results are good.
  • A
    Anonymous
    Kind of same action after Dravet Syndrome or Lennox-Gastaut Syndrome results. People were looking for miracle drug? I think it get approved as they need other options in these hard to treat diseases. No side effects and long acting effects.
  • C
    Christian
    I would love somebody on this board to answer a question. And that question is if OVID is going to have the big Webinar on Oct. 22nd WHY IS THIS STOCK NOT $10???? This is whats happening on Thursday, October 22, at 1:00 p.m. ET to review multiple aspects of Angelman syndrome, including its biological mechanism, and the Company’s OV101 (gaboxadol) development program. The webinar will feature external experts discussing topics that includes the role of tonic inhibition, treatment practice in Angelman syndrome, measurement scales and what to expect from the pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome.
  • K
    Kash
    Bullish
  • m
    minevl
    Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA...
    Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA...
    www.globenewswire.com
  • A
    Anonymous
    Seems like an over reaction or sell on the news since OVID ran up hard before data. Offering buyers were happy to pay $8. Data from Lennox-Gastaut syndrome missed efficacy by only a few points. I can see off label use in this hard to treat patients or maybe they find something in the data to move further. CDKL5 deficiency disorder and Dup15q syndrome, two other types of highly-refractory DEEs, later this quarter."
  • t
    treydur
    A number of other equities research analysts also recently weighed in on OVID. William Blair reissued a "buy" rating on shares of Ovid Therapeutics in a report on Tuesday, August 11th. LADENBURG THALM/SH SH restated a "buy" rating and set a $21.00 price target on shares of Ovid Therapeutics in a report on Monday, July 13th. Citigroup boosted their price target on Ovid Therapeutics from $9.00 to $10.00 and gave the stock a "buy" rating in a report on Wednesday, August 26th. Zacks Investment Research cut Ovid Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Finally, Cantor Fitzgerald reduced their target price on Ovid Therapeutics from $13.00 to $12.00 in a report on Wednesday, August 26th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company's stock. The stock currently has an average rating of "Buy" and a consensus price target of $13.18.
  • B
    Big Pharma
    Ovid is a promising company with a strong pipeline. The lack of treatments for Angelman and positive clinical data from Neptune, showing improvements in key endpoints, means that OV101 may potentially be used as a first line treatment by clinicians. It's also an oral treatment which eases burden of administration. OV101 doesn't treat the underlying cause but it seems to improve patients lives and will likely be used until gene therapy provides a cure. Other positives relate to Ovid's management team (Levin was former CEO of Teva). So there is confidence that he will not run the company into the ground. Competition is relatively scarce in this area and Ovids trials seem to be one the most advanced which means potentially first to market. The only concern I have currently with the company is thier cash position (but it doesn't bother me too much). I'm reading a lot of comments here about people wanting to sell their shares now, which seems a bit mad really given the potential for FDA approval and growth in medium term. If you truly understood the stock and what you have invested in then, that thought shouldn't really enter your mind. The only reason to sell is disastrous clinical data showing no effect (but so far so good). To quote Ryanair, sit back, relax and enjoy the flight.
    Bullish
  • J
    Jason
    Neutral for a while and bullish on long term. Those who've been holding since very low will know this very particular behavior of this stock ! It finally tasted a new high today of $9. I personally expect it to go sideways for 2-3 weeks before stabilizing in the $11 range. It's a stock market, we got to be realistic. But Ovid has the potential to hit those $20, add in more if it tastes new lows for whatever reason. With all my honesty, expect to taste the $20 only after a quarter of exposing the drug on the market. If it happens well before that, then congrats to you all !
  • A
    Anthony
    Why am I seeing pages post that Ovid revenue estimates were slashed for 2021 but then stating they went from 4.4M to 7.7M? I'm sure I'm reading something incorrectly and just drawing a blank on it.
  • G
    Gordon
    The ever strange phenomenon of short cash creating spikes across many bios this morning. I didn't sell cause I think we'll see larger gains on future milestone news.
    Bullish
  • J
    Jason
    Greetings Shareholders, i know some of you might not be in best shape right now looking at what's happening to our stock, but stay solid and strong. By July 17th let's hope something moves this stock. The harsh and severe pullback right now doesn't surprise me at all, i'm one of those who were here at $2 and i warned you to be strong in my previous post, a pull back and sideways was coming. Ride the wave and take care all.
    Neutral
Advertisement
Advertisement